Monte Rosa Therapeutics GLUE
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$3.72M (3 inflow days, 17 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 38.7% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 20.46% to 24.45% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Silverarc Capital Management, LLC | Hedge Fund | 2026/Q3 | +2,004,478 | 3.6% |
| Morgan Stanley | Public Company | 2026/Q3 | +357,635 | 1.3% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +357,635 | 1.3% |
| BlackRock | Mutual Fund | 2026/Q3 | +349,359 | 8.4% |
| Y-Intercept (Hong Kong) Limited | Mutual Fund | 2026/Q3 | +205,172 | 0.3% |
| Squarepoint OPS LLC | Hedge Fund | 2026/Q3 | +204,627 | 0.3% |
| Dimensional Fund Advisors | Mutual Fund | 2026/Q3 | +203,856 | 1.6% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +189,430 | 0.2% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +2,140,983 | 10.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +1,205,403 | 8.0% |
| Vestal Point Capital, LP | Hedge Fund | 2026/Q3 | +996,535 | 5.4% |
| Woodline Partners LP | Hedge Fund | 2026/Q3 | +888,388 | 1.1% |
| Opaleye Management Inc. | Hedge Fund | 2026/Q3 | +745,000 | 0.9% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +647,796 | 0.8% |
| Boone Capital Management LLC | Hedge Fund | 2026/Q3 | +615,287 | 0.7% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 4 Oct 2026 | Matthew Bowen | Corporate Controller & Principal Accounting Officer | Open Market Disposition | -13 | $10.56 | 18,001 |
| 15 Jul 2026 | Markus Warmuth | Chief Executive Officer | Open Market Disposition | -9,500 | $23.18 | 399,038 |
| 14 Jul 2026 | Jennifer Champoux | Chief Operating Officer | Derivative Exercise and Sale | -4,351 | $23.38 | 4,871 |
| 5 Jul 2026 | Sharon Townson | Chief Scientific Officer | Derivative Exercise and Sale | -6,000 | $24.13 | 5,845 |
| 30 Jun 2026 | New Enterprise Associates, Inc. | Other Acquisition | +15,000 | – | 6,692,298 | |
| 30 Jun 2026 | New Enterprise Associates, Inc. | Other Disposition | -1,015,000 | – | 6,692,298 | |
| 29 Jun 2026 | Filip Janku | Chief Medical Officer | Derivative Exercise and Sale | -5,407 | $24.50 | 2,612 |
| 28 Jun 2026 | Anthony Manning | Independent Director | Derivative Exercise and Sale | -10,000 | $23.11 | – |
| 28 Jun 2026 | Filip Janku | Chief Medical Officer | Derivative Exercise and Sale | -6,000 | $22.95 | 1,992 |
| 23 Jun 2026 | Filip Janku | Chief Medical Officer | Intent to Sell (Form 144) | -30,000 | $20.71 | – |
| 23 Jun 2026 | Filip Janku | Chief Medical Officer | Derivative Exercise and Sale | -36,000 | $21.42 | 1,992 |
| 22 Jun 2026 | Filip Janku | Chief Medical Officer | Automatic Disposition | -5,845 | $20.22 | 1,992 |
| 22 Jun 2026 | Sharon Townson | Chief Scientific Officer | Derivative Exercise and Sale | -3,000 | $20.00 | 5,845 |
| 22 Jun 2026 | Jennifer Champoux | Chief Operating Officer | Derivative Exercise and Sale | -2,175 | $20.00 | 4,871 |
| 16 Jun 2026 | Sharon Townson | Chief Scientific Officer | Derivative Exercise and Sale | -3,000 | $19.00 | 5,845 |
| 16 Jun 2026 | Jennifer Champoux | Chief Operating Officer | Derivative Exercise and Sale | -2,176 | $19.00 | 4,871 |
| 10 Jun 2026 | Christine Siu | Independent Director | Other Derivative Acquisition | +25,800 | $17.10 | 25,800 |
| 10 Jun 2026 | Andrew Schiff | Independent Chairperson | Other Derivative Acquisition | +25,800 | $17.10 | 25,800 |
| 10 Jun 2026 | Anthony Manning | Independent Director | Other Derivative Acquisition | +25,800 | $17.10 | 25,800 |
| 10 Jun 2026 | Jan Skvarka | Independent Director | Other Derivative Acquisition | +25,800 | $17.10 | 25,800 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 20,856,472 | 24.4% | 15.7 |
| 15 Oct 2026 | 20,660,257 | 24.2% | 11.2 |
| 30 Sep 2026 | 19,686,241 | 23.1% | 18.0 |
| 15 Sep 2026 | 19,265,990 | 22.6% | 17.1 |
| 31 Aug 2026 | 18,075,786 | 21.2% | 16.6 |
| 14 Aug 2026 | 17,457,317 | 20.5% | 14.0 |
No comments yet — be the first to weigh in on GLUE.
Sign in to join the discussion.